Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

ON-AIR 🟢 - Poo-tane Gas 50 min · 23 Sep 2026 · The Morning Rumble

Lemon LIVE at 5: Trump's Attack on the Media is an Attack on Democracy 57 min · 23 Sep 2026 · The Don Lemon Show

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

NPR News: 09-23-2026 6PM EDT 5 min · 23 Sep 2026 · NPR News Now

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

H3 Tim Grunhard 39 min · 23 Sep 2026 · The Program

Report any issue

Source

Recorded28 Nov 2025

Publisherc.answersincme.com ↗

Handlerec:13455820

Show notes

Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in